Vessi Medical, an Israeli company, closed a $16.5 million Series A funding round for its cryotherapy technology to treat non muscle invasive bladder cancer (NMIBC). The company’s cryo spray aims to offer a minimally invasive alternative to the surgical first-line therapy for NMIBC. ALIVE- Israel HealthTech Fund, Agriline, and a strategic investor led the investment. Vessi plans to use the funding to expand its R&D capabilities, conduct clinical studies, and obtain regulatory clearance. In a separate announcement, Merit Medicine, a company offering AI technology to self-funded employers for predicting healthcare costs, closed a $2 million seed round led by LiveOak Ventures. The AI technology aims to help employers predict budgeting needs based on patient journeys and identify potential high-cost medical expenditures.
Source link
Cryotherapy technology company Vessi Medical scores $16.5M and more digital health fundings
